CBM accelerates plans to add capacity for 10,000 patient therapies
The Center for Breakthrough Medicines (CBM) and Discovery Labs respond to the critical shortage of cell therapies by accelerating plans to build capacity to produce over 10,000 patient therapies.
The plant expansion at CBM’s King of Prussia, Philadelphia, which was initially outlined to begin planning in 2024-2025, has now been started due to “the critical lack of cell therapy supply,” a spokesperson for CBM told us.
“We are also seeing shortages for already approved products, long waitlists, and doctors being forced to choose which of their patients get the scarce CAR T manufacturing slot for their treatment center. We want to make sure there is capacity available when many of the products now in the clinic become commercial.”